================================================================================
PHARMACY SALES PRESCRIPTIVE RECOMMENDATIONS
Generated: 2025-10-05 22:07:40
================================================================================

üì¶ INVENTORY MANAGEMENT RECOMMENDATIONS:

  ‚úì HIGH PRIORITY REORDERS (Top 5 by demand):
    ‚Ä¢ RETASAR (LOSARTAN POTASSIUM) 50MG: Reorder when stock falls below 410 units
      - Maintain safety stock of 212 units
      - Expected demand (30 days): 578 units
    ‚Ä¢ RETAZART (LOSARTAN) 50MG TAB: Reorder when stock falls below 367 units
      - Maintain safety stock of 177 units
      - Expected demand (30 days): 1617 units
    ‚Ä¢ OHHIRA&#039;S RED OMX PROBIOTICS CAP: Reorder when stock falls below 159 units
      - Maintain safety stock of 67 units
      - Expected demand (30 days): 379 units
    ‚Ä¢ RETANIX (CETIRIZINE) 10MG TAB: Reorder when stock falls below 260 units
      - Maintain safety stock of 179 units
      - Expected demand (30 days): 324 units
    ‚Ä¢ BIOGESIC 500MG TAB: Reorder when stock falls below 319 units
      - Maintain safety stock of 240 units
      - Expected demand (30 days): 552 units

üìã ORDERING STRATEGY RECOMMENDATIONS:

  ‚úì OPTIMAL ORDER QUANTITIES (Top 5 products):
    ‚Ä¢ RETASAR (LOSARTAN POTASSIUM) 50MG: Order 2133 units every 85 days
      - This minimizes total cost to $23,399.53/year
    ‚Ä¢ OHHIRA&#039;S RED OMX PROBIOTICS CAP: Order 341 units every 26 days
      - This minimizes total cost to $242,364.62/year
    ‚Ä¢ BIOGESIC 500MG TAB: Order 1076 units every 96 days
      - This minimizes total cost to $18,440.18/year
    ‚Ä¢ RETANIX (CETIRIZINE) 10MG TAB: Order 1414 units every 127 days
      - This minimizes total cost to $10,709.91/year
    ‚Ä¢ APPEVIT (BUCLIZINE HCL+B-COMPLEX+IRON) CAP: Order 528 units every 57 days
      - This minimizes total cost to $51,326.67/year

üí∞ BUDGET ALLOCATION RECOMMENDATIONS:

  ‚úì PRIORITIZE INVESTMENT IN:
    ‚Ä¢ AMLOSAPH (AMLODIPINE) 10MG TAB: Allocate 135987 units ($260,432.08)
      - Expected profit: $222,355.72

üíµ PRICING & DISCOUNT RECOMMENDATIONS:

  ‚úì MAINTAIN/INCREASE DISCOUNTS FOR:
    ‚Ä¢ BETTER C (ASCORBIC ACID ) 500MG TAB: Current discount 0.0% is highly efficient
      - Generates 9500.0 units per dollar of discount
    ‚Ä¢ MERIDON (DOMPERIDONE) 10MG FC TAB: Current discount 0.1% is highly efficient
      - Generates 1120.0 units per dollar of discount
    ‚Ä¢ AMLOPIGEN 5MG (AMLODIPINE BESILATE: Current discount 0.1% is highly efficient
      - Generates 1000.0 units per dollar of discount

  ‚úì REDUCE/ELIMINATE DISCOUNTS FOR:
    ‚Ä¢ LIPITOR TAB 20MG: Low efficiency (42.7 units/$)
      - Consider reducing discount from 0.1%
    ‚Ä¢ MAXIVENT 400MG TAB: Low efficiency (42.5 units/$)
      - Consider reducing discount from 0.1%
    ‚Ä¢ XIPRO TAB 500MG: Low efficiency (42.5 units/$)
      - Consider reducing discount from 0.1%

üìà SALES GROWTH OPPORTUNITIES:

  ‚úì PROMOTE HIGH-MARGIN PRODUCTS:
    ‚Ä¢ #EXP2025-03-30: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ #EXP2025-03-31: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ #EXP2026-07-30: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ #EXP2027-05-24: 100.0% margin
      - Increase visibility and marketing for this product
    ‚Ä¢ ALCIFLORA (BACILLUS CLAUSII) 5ML: 100.0% margin
      - Increase visibility and marketing for this product

  ‚úì PRODUCTS WITH GROWTH POTENTIAL:
    ‚Ä¢ RETASAR (LOSARTAN POTASSIUM) 50MG: Steady demand (28.3 units/day)
      - Consider promotional campaigns to boost sales
    ‚Ä¢ OHHIRA&#039;S RED OMX PROBIOTICS CAP: Steady demand (13.1 units/day)
      - Consider promotional campaigns to boost sales
    ‚Ä¢ BIOGESIC 500MG TAB: Steady demand (11.2 units/day)
      - Consider promotional campaigns to boost sales

‚öôÔ∏è OPERATIONAL EFFICIENCY RECOMMENDATIONS:

  ‚úì INVESTIGATE ANOMALOUS SALES DAYS:
    ‚Ä¢ 36 days showed unusual patterns
    ‚Ä¢ Review these dates for:
      - Stock-outs or supply issues
      - Unexpected demand spikes
      - Data entry errors
    ‚Ä¢ 2024-09-18: Sales $118,645.44 (Score: -0.82)
    ‚Ä¢ 2024-09-25: Sales $96,570.61 (Score: -0.78)
    ‚Ä¢ 2024-03-21: Sales $66,970.49 (Score: -0.70)

üèóÔ∏è RESOURCE PLANNING RECOMMENDATIONS:

  ‚úì PREPARE FOR NEXT 90 DAYS:
    ‚Ä¢ Total storage space needed: 80,474 cubic feet
    ‚Ä¢ Total capital required: $1,305,566.98
    ‚Ä¢ Ensure adequate:
      - Warehouse capacity
      - Working capital/credit lines
      - Staff for inventory management

üë• CUSTOMER SEGMENT STRATEGY:

  ‚úì CUSTOMER GROUP INSIGHTS:
    ‚Ä¢ Regular:
      - Sales: $7,022,744.83
      - Profit Margin: 24.3%
      - Units Sold: 202,309
    ‚Ä¢ Senior/PWD:
      - Sales: $1,801,920.87
      - Profit Margin: 12.7%
      - Units Sold: 69,665

üéØ QUICK WINS (Immediate Actions):

  ‚úì THIS WEEK:
    1. Review and adjust reorder points for top 10 products
    2. Implement EOQ-based ordering for high-volume items
    3. Analyze anomalous sales days and document findings

  ‚úì THIS MONTH:
    1. Optimize discount strategy based on efficiency analysis
    2. Reallocate budget to high-margin products
    3. Set up automated reorder alerts at calculated ROP levels
    4. Train staff on new inventory management procedures

  ‚úì THIS QUARTER:
    1. Implement full resource planning system
    2. Develop customer segment-specific marketing campaigns
    3. Review and optimize supplier relationships
    4. Establish KPIs and monitoring dashboards

‚ö†Ô∏è RISK MITIGATION:

  ‚úì MONITOR CLOSELY:
    ‚Ä¢ High demand variability products:
      - AMVASC BE (AMLODIPINE) 5MG TAB: CV = 1272.0%
        ‚Üí Maintain higher safety stock
      - BIOGESIC 500MG TAB: CV = 491.6%
        ‚Üí Maintain higher safety stock
      - RETASAR (LOSARTAN POTASSIUM) 50MG: CV = 172.2%
        ‚Üí Maintain higher safety stock